Serina Therapeutics receives NYSE American deficiency notice for stockholders' equity below $2M

Serina Therapeutics, Inc.

Stockholders' equity was $1.6M as of Sept 30, 2025, below $2M, $4M, and $6M thresholds.
Company has until Feb 8, 2026 to submit a plan to regain compliance by July 9, 2027.
Non-compliance triggers NYSE American Section 1009; delisting proceedings may start if plan rejected.
Company intends to submit a plan but cannot assure compliance during the 18-month cure period.

item 3.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.